Viral methyltransferase inhibitors: berbamine, venetoclax, and ponatinib as efficacious antivirals against Chikungunya virus
Abstract
Chikungunya virus (CHIKV), transmitted by mosquitoes, poses a significant global health threat. Presently, no effective treatment options are available to reduce the disease burden. The lack of approved therapeutics against CHIKV and the complex spectrum of chronic musculoskeletal and neurological manifestations raise significant concerns, and repurposing drugs could offer swift avenues in the development of effective treatment strategies. RNA capping is a crucial step meditated by non-structural protein 1 (nsP1) in CHIKV replication. In this study, FDA-approved antivirals targeting CHIKV nsP1 methyltransferase (MTase) have been identified by structure-based virtual screening. Berbamine Hydrochloride (BH), ABT199/Venetoclax (ABT), and Ponatinib (PT) were the top hits, which exhibited robust binding energies. Tryptophan fluorescence spectroscopy-based assay confirmed binding of BH-, ABT-, and PT to purified nsP1 with KD values [~]5.45 M, [~]161.3 M, and [~]3.83M, respectively. A dose-dependent decrease in CHIKV nsP1 MTase activity was observed in a capillary electrophoresis-based assay. Treatment with BH, ABT, and PT lead to a dose-dependent reduction in the virus titer with IC50 1.25 M, respectively. These results underscore the efficacy and promise of repurposing drugs as rapid and effective antiviral therapeutics against CHIKV. HighlightsO_LIBerbamine Hydrochloride (BH), ABT199/Venetoclax (ABT), and Ponatinib (PT) identified as inhibitors of Chikungunya virus (CHIKV) nsP1 C_LIO_LIMolecules BH, ABT and PT make moelcular interactions with nsP1: KD values [~]5.45, [~]161.3, and [~]3.83 in M, respectively and effectively inhibit methyltransferase activity. C_LIO_LIBH, ABT, and PT exhibited potent antiviral activity against CHIKV in cell-based assays, with IC50 1.25 M respectively demonstrating broad spectrum antiviral efficacy. C_LI Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=117 SRC="FIGDIR/small/594723v1_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@1af985dorg.highwire.dtl.DTLVardef@13c14fforg.highwire.dtl.DTLVardef@1868785org.highwire.dtl.DTLVardef@12b690a_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 22
- FWCI
- 7.59
- Field percentile
- top 2%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Serotonergic drugs inhibit CHIKV infection at different stages of the cell entry pathway
E. M. Bouma, D. P. I. van de Pol, … J. M. Smit·bioRxiv·Mar 24, 2020
- New highly selective antivirals for Chikungunya Virus identified from the screening of a drug-like compound library
Eliana F. Castro, Diego Ezequiel Alvarez·Current MicrobiologyPeer-reviewed·Sep 3, 2024
- Repurposing efavirenz, the HIV antiretroviral drug for Chikungunya virus infection.
Sanketkumar Nehul, Ruchi Rani, … Shailly Tomar·ACS Infectious DiseasesPeer-reviewed·Mar 7, 2025
- Emetine dihydrochloride inhibits Chikungunya virus nsP2 helicase and shows antiviral activity in the cell culture and mouse model of virus infection
Anshula Sharma, Chandru Subramani, … Sudhanshu Vrati·bioRxiv·Jun 20, 2025
- Drug Repurposing: A Potential Therapeutic Strategy for the Treatment of Chikugunya Virus
Siphokazi Zondi, Letitia Shunmugam, … Hezekiel Mathambo Kumalo·bioRxiv·Feb 19, 2026
- Identification and Characterization of Novel Chikungunya Virus Polymerase Inhibitors
Peiqi Yin, Ryan Boyce, … Robert M. Cox·Journal of VirologyPeer-reviewed·May 19, 2026